Pivotal CAR-T therapy cancer study published in the New England Journal of MedicinePR Newswire (press release)"For nearly a decade, John Theurer Cancer Center has been involved in CAR T-Cell research and the developments that led to the approval o… Continue reading
Pivotal CAR-T therapy cancer study published in the New England Journal of MedicinePR Newswire (press release)"For nearly a decade, John Theurer Cancer Center has been involved in CAR T-Cell research and the developments that led to the approval o… Continue reading
Myeloma Research NewsBioLineRx Readies Phase 3 Myeloma Trial to Mobilize Stem Cells for TransplantMyeloma Research NewsBioLineRx has launched a Phase 3 trial to assess if adding BL-8040 to standard treatment will improve the outflux of blood stem cells… Continue reading
Stem Cell Institute of America – December 22, 20179NEWS.comStem Cell Institute of America – December 22, 2017. Error loading player: No playable sources found. To find out if surgery-free, stem cell treatments can help relieve your joint pain inquire a… Continue reading
Genetic Engineering & Biotechnology News |
New technique could reveal immunotherapy targets, study finds
Science Daily Antigens are cumbersome to identify but critical to developing cancer immunotherapies, a type of treatment in which the host’s own immune system is trained to seek out and fight harmful or mutated cells. And while cancer vaccines are still largely a … Cancer Antigens Discerned by Seeing Them through Immune Cell EyesGenetic Engineering & Biotechnology News |
Drug Discovery & Development |
Janssen, Legend Biotech Strike Collaboration and License Agreement to Develop Investigational CAR–T Anti-Cancer …
Drug Discovery & Development Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, announced that it has entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited (“Legend”), subsidiaries of … Janssen buys into Legend’s CART therapyPharmaTimes Chinese biotech firm Genscript’s shares jump by a third on US$350m Johnson & Johnson unit tie-upSouth China Morning Post |